Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

Em­ploy­ers who of­fer in­sur­ance cov­er­age of the new class of obe­si­ty med­ica­tions could dou­ble next year, ac­cord­ing to a new sur­vey of 500 em­ploy­ers. Con­duct­ed

A Eu­ro­pean start­up is bet­ting that drug com­pa­nies big and small will look to out­source ar­ti­fi­cial in­tel­li­gence ex­per­tise that can help de­sign new pro­tein-based med­i­cines.

The FDA re­ceived an of­fi­cial go-ahead from HHS on Thurs­day, set­ting in­to mo­tion its planned re­or­ga­ni­za­tion of its in­spec­tion op­er­a­tions around the globe, with an